 Gregory Kinney
Concepts (377)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 47 | 2023 | 1419 | 4.580 |
Why?
| | Coronary Artery Disease | 26 | 2021 | 698 | 1.910 |
Why?
| | Tomography, X-Ray Computed | 40 | 2022 | 2462 | 1.880 |
Why?
| | Diabetes Mellitus, Type 1 | 37 | 2022 | 3258 | 1.840 |
Why?
| | Smoking | 22 | 2023 | 1654 | 1.400 |
Why?
| | Smokers | 13 | 2023 | 175 | 1.340 |
Why?
| | Pulmonary Emphysema | 11 | 2023 | 371 | 1.270 |
Why?
| | Calcinosis | 17 | 2015 | 294 | 1.090 |
Why?
| | Forced Expiratory Volume | 20 | 2023 | 599 | 1.080 |
Why?
| | Respiratory Function Tests | 11 | 2021 | 596 | 0.990 |
Why?
| | Bronchiectasis | 6 | 2022 | 105 | 0.980 |
Why?
| | Diabetic Ketoacidosis | 3 | 2022 | 164 | 0.970 |
Why?
| | Cannabis | 7 | 2023 | 340 | 0.950 |
Why?
| | Dronabinol | 3 | 2021 | 114 | 0.910 |
Why?
| | Marijuana Smoking | 3 | 2022 | 233 | 0.910 |
Why?
| | Lung | 17 | 2023 | 3645 | 0.820 |
Why?
| | Diabetic Angiopathies | 11 | 2016 | 274 | 0.780 |
Why?
| | Volatilization | 1 | 2019 | 61 | 0.770 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 82 | 0.740 |
Why?
| | Cannabinoids | 4 | 2023 | 116 | 0.720 |
Why?
| | Middle Aged | 77 | 2022 | 28659 | 0.680 |
Why?
| | Coronary Vessels | 7 | 2021 | 260 | 0.630 |
Why?
| | Air Pollution | 1 | 2019 | 188 | 0.630 |
Why?
| | Marijuana Abuse | 1 | 2019 | 220 | 0.620 |
Why?
| | Risk Factors | 33 | 2023 | 9124 | 0.580 |
Why?
| | Female | 93 | 2023 | 63247 | 0.570 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2016 | 24 | 0.560 |
Why?
| | Vascular Calcification | 5 | 2019 | 125 | 0.560 |
Why?
| | Disease Progression | 24 | 2021 | 2541 | 0.540 |
Why?
| | Male | 86 | 2022 | 60403 | 0.540 |
Why?
| | Risk Assessment | 8 | 2019 | 3208 | 0.520 |
Why?
| | Humans | 111 | 2023 | 117633 | 0.510 |
Why?
| | Aged | 37 | 2022 | 20249 | 0.480 |
Why?
| | Spirometry | 10 | 2023 | 313 | 0.420 |
Why?
| | Coronary Disease | 7 | 2010 | 408 | 0.410 |
Why?
| | Cohort Studies | 25 | 2022 | 5112 | 0.410 |
Why?
| | Prospective Studies | 23 | 2022 | 6422 | 0.410 |
Why?
| | Emphysema | 2 | 2023 | 125 | 0.400 |
Why?
| | Pulmonary Artery | 4 | 2022 | 1073 | 0.390 |
Why?
| | Adult | 47 | 2022 | 32118 | 0.370 |
Why?
| | Depression | 4 | 2022 | 1196 | 0.360 |
Why?
| | Lipoproteins | 3 | 2016 | 171 | 0.360 |
Why?
| | Pectoralis Muscles | 3 | 2021 | 22 | 0.360 |
Why?
| | Albuminuria | 4 | 2016 | 185 | 0.350 |
Why?
| | Calcium | 7 | 2018 | 1203 | 0.330 |
Why?
| | Metformin | 2 | 2021 | 291 | 0.330 |
Why?
| | Severity of Illness Index | 15 | 2023 | 2884 | 0.320 |
Why?
| | Prevalence | 11 | 2023 | 2438 | 0.320 |
Why?
| | Marijuana Use | 2 | 2021 | 157 | 0.310 |
Why?
| | Case-Control Studies | 14 | 2019 | 3269 | 0.300 |
Why?
| | Tandem Mass Spectrometry | 2 | 2019 | 389 | 0.300 |
Why?
| | Predictive Value of Tests | 10 | 2019 | 1971 | 0.300 |
Why?
| | Hypnotics and Sedatives | 2 | 2019 | 135 | 0.290 |
Why?
| | Quality of Life | 4 | 2021 | 2354 | 0.290 |
Why?
| | Proportional Hazards Models | 6 | 2019 | 1199 | 0.280 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2016 | 2031 | 0.280 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2023 | 66 | 0.280 |
Why?
| | Cause of Death | 2 | 2018 | 399 | 0.280 |
Why?
| | Antidepressive Agents | 3 | 2019 | 203 | 0.270 |
Why?
| | Body Mass Index | 10 | 2022 | 2076 | 0.270 |
Why?
| | Bronchi | 2 | 2016 | 250 | 0.270 |
Why?
| | Biomarkers | 11 | 2022 | 3574 | 0.270 |
Why?
| | Renal Insufficiency | 2 | 2016 | 133 | 0.270 |
Why?
| | Genetic Predisposition to Disease | 6 | 2019 | 2206 | 0.270 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 226 | 0.260 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2017 | 359 | 0.260 |
Why?
| | Symptom Flare Up | 2 | 2021 | 38 | 0.250 |
Why?
| | Fibrinogen | 3 | 2014 | 161 | 0.240 |
Why?
| | Atherosclerosis | 3 | 2019 | 314 | 0.240 |
Why?
| | Propofol | 2 | 2021 | 43 | 0.240 |
Why?
| | Logistic Models | 12 | 2017 | 2018 | 0.240 |
Why?
| | Adiponectin | 4 | 2016 | 213 | 0.230 |
Why?
| | Vital Capacity | 4 | 2021 | 277 | 0.230 |
Why?
| | Limit of Detection | 2 | 2019 | 54 | 0.230 |
Why?
| | Young Adult | 14 | 2022 | 11077 | 0.230 |
Why?
| | Aged, 80 and over | 9 | 2022 | 6795 | 0.230 |
Why?
| | Cannabidiol | 1 | 2023 | 55 | 0.230 |
Why?
| | Umbilical Cord | 2 | 2021 | 88 | 0.220 |
Why?
| | Ketosis | 1 | 2022 | 14 | 0.220 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 81 | 0.220 |
Why?
| | Follow-Up Studies | 10 | 2022 | 4911 | 0.220 |
Why?
| | Cystatin C | 3 | 2011 | 70 | 0.220 |
Why?
| | Sarcopenia | 1 | 2022 | 59 | 0.220 |
Why?
| | Hallucinogens | 1 | 2023 | 70 | 0.220 |
Why?
| | Cholesterol | 4 | 2011 | 391 | 0.220 |
Why?
| | Molecular Epidemiology | 2 | 2019 | 60 | 0.220 |
Why?
| | Protective Agents | 1 | 2021 | 43 | 0.210 |
Why?
| | Hand Strength | 2 | 2022 | 105 | 0.210 |
Why?
| | Cardiovascular Diseases | 4 | 2017 | 1717 | 0.210 |
Why?
| | Self Report | 3 | 2021 | 715 | 0.210 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2021 | 85 | 0.200 |
Why?
| | C-Reactive Protein | 2 | 2014 | 357 | 0.200 |
Why?
| | Cross-Sectional Studies | 11 | 2021 | 4630 | 0.200 |
Why?
| | Muscular Atrophy | 1 | 2021 | 85 | 0.200 |
Why?
| | Hepatitis C | 1 | 2023 | 224 | 0.190 |
Why?
| | Delirium | 1 | 2021 | 70 | 0.190 |
Why?
| | 2-Propanol | 1 | 2019 | 21 | 0.190 |
Why?
| | Osteoporosis | 1 | 2022 | 213 | 0.190 |
Why?
| | Pulmonary Heart Disease | 1 | 2019 | 7 | 0.190 |
Why?
| | Foam Cells | 1 | 2019 | 19 | 0.190 |
Why?
| | Hyperostosis | 1 | 2019 | 6 | 0.190 |
Why?
| | Calibration | 1 | 2019 | 137 | 0.190 |
Why?
| | Diabetic Nephropathies | 2 | 2016 | 290 | 0.190 |
Why?
| | Genetic Markers | 2 | 2019 | 349 | 0.180 |
Why?
| | Airway Obstruction | 1 | 2021 | 167 | 0.180 |
Why?
| | Carbon Monoxide | 1 | 2019 | 70 | 0.180 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2019 | 177 | 0.180 |
Why?
| | Blood Glucose | 6 | 2022 | 1904 | 0.180 |
Why?
| | Anti-Anxiety Agents | 1 | 2019 | 48 | 0.180 |
Why?
| | Drug Overdose | 1 | 2022 | 271 | 0.170 |
Why?
| | Genome-Wide Association Study | 4 | 2019 | 1036 | 0.170 |
Why?
| | Surface Properties | 1 | 2019 | 396 | 0.170 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 142 | 0.170 |
Why?
| | United States | 9 | 2022 | 12768 | 0.170 |
Why?
| | Diabetes Complications | 2 | 2010 | 226 | 0.170 |
Why?
| | Adipose Tissue | 2 | 2017 | 665 | 0.170 |
Why?
| | Insulin Resistance | 4 | 2017 | 1163 | 0.170 |
Why?
| | Vascular Remodeling | 1 | 2019 | 147 | 0.170 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2019 | 206 | 0.170 |
Why?
| | Factor Analysis, Statistical | 1 | 2018 | 294 | 0.160 |
Why?
| | Urine | 1 | 2017 | 61 | 0.160 |
Why?
| | Longitudinal Studies | 6 | 2021 | 2668 | 0.160 |
Why?
| | Heart Ventricles | 2 | 2020 | 756 | 0.160 |
Why?
| | HIV Infections | 2 | 2023 | 2512 | 0.160 |
Why?
| | Organ Size | 4 | 2021 | 493 | 0.160 |
Why?
| | Environmental Monitoring | 1 | 2019 | 291 | 0.160 |
Why?
| | Phenotype | 4 | 2019 | 2875 | 0.160 |
Why?
| | Population Surveillance | 1 | 2021 | 449 | 0.160 |
Why?
| | Polymorphism, Genetic | 3 | 2011 | 636 | 0.160 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2017 | 32 | 0.160 |
Why?
| | Linear Models | 6 | 2019 | 871 | 0.160 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2023 | 499 | 0.150 |
Why?
| | Machine Learning | 1 | 2019 | 271 | 0.150 |
Why?
| | Bronchitis, Chronic | 1 | 2016 | 27 | 0.150 |
Why?
| | Obesity | 4 | 2022 | 2711 | 0.150 |
Why?
| | Prenatal Care | 1 | 2019 | 260 | 0.150 |
Why?
| | Anxiety | 2 | 2022 | 867 | 0.150 |
Why?
| | Aortography | 1 | 2015 | 45 | 0.140 |
Why?
| | Plasma | 1 | 2017 | 226 | 0.140 |
Why?
| | Intraoperative Neurophysiological Monitoring | 1 | 2015 | 14 | 0.140 |
Why?
| | Dyspnea | 3 | 2023 | 199 | 0.140 |
Why?
| | Dexmedetomidine | 1 | 2015 | 47 | 0.140 |
Why?
| | Respiratory System | 1 | 2016 | 142 | 0.140 |
Why?
| | Comorbidity | 5 | 2021 | 1650 | 0.140 |
Why?
| | Exercise Tolerance | 3 | 2023 | 251 | 0.140 |
Why?
| | Periodontal Diseases | 1 | 2015 | 80 | 0.140 |
Why?
| | Multivariate Analysis | 5 | 2019 | 1584 | 0.130 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2019 | 1777 | 0.130 |
Why?
| | Adiposity | 2 | 2022 | 504 | 0.130 |
Why?
| | Respiratory Muscles | 1 | 2014 | 30 | 0.130 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2017 | 159 | 0.130 |
Why?
| | Evoked Potentials, Somatosensory | 2 | 2015 | 57 | 0.130 |
Why?
| | Evoked Potentials | 1 | 2015 | 162 | 0.130 |
Why?
| | Regression Analysis | 5 | 2017 | 1072 | 0.130 |
Why?
| | Endothelium, Vascular | 1 | 2021 | 928 | 0.130 |
Why?
| | Subcutaneous Fat | 1 | 2014 | 90 | 0.130 |
Why?
| | Spine | 1 | 2015 | 137 | 0.130 |
Why?
| | Health Status | 2 | 2022 | 791 | 0.120 |
Why?
| | Pregnancy Complications | 1 | 2019 | 474 | 0.120 |
Why?
| | Heart | 1 | 2017 | 655 | 0.120 |
Why?
| | Body Composition | 4 | 2021 | 765 | 0.120 |
Why?
| | Up-Regulation | 1 | 2016 | 900 | 0.120 |
Why?
| | Sex Distribution | 5 | 2014 | 390 | 0.120 |
Why?
| | Orthopedic Procedures | 1 | 2015 | 209 | 0.120 |
Why?
| | Aorta | 1 | 2015 | 425 | 0.110 |
Why?
| | Colorado | 6 | 2021 | 4401 | 0.110 |
Why?
| | Blood Pressure | 4 | 2017 | 1680 | 0.110 |
Why?
| | Haptoglobins | 1 | 2011 | 30 | 0.110 |
Why?
| | Blood Vessels | 1 | 2013 | 192 | 0.110 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1703 | 0.110 |
Why?
| | Triglycerides | 2 | 2011 | 551 | 0.110 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 556 | 0.110 |
Why?
| | Registries | 1 | 2019 | 1969 | 0.100 |
Why?
| | Occupational Exposure | 1 | 2014 | 314 | 0.100 |
Why?
| | Adolescent | 6 | 2022 | 18902 | 0.100 |
Why?
| | Retrospective Studies | 8 | 2021 | 12331 | 0.100 |
Why?
| | Pediatric Obesity | 1 | 2017 | 435 | 0.100 |
Why?
| | Walk Test | 2 | 2021 | 60 | 0.100 |
Why?
| | Alcohol Drinking | 2 | 2009 | 711 | 0.100 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 10 | 0.100 |
Why?
| | Coma | 1 | 2009 | 39 | 0.100 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 444 | 0.090 |
Why?
| | Patient Education as Topic | 2 | 2005 | 720 | 0.090 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2009 | 27 | 0.090 |
Why?
| | Monitoring, Intraoperative | 1 | 2009 | 36 | 0.090 |
Why?
| | Facial Nerve | 1 | 2009 | 34 | 0.090 |
Why?
| | Lymphatic Abnormalities | 1 | 2009 | 14 | 0.090 |
Why?
| | Respiratory Physiological Phenomena | 2 | 2022 | 30 | 0.090 |
Why?
| | Aortic Diseases | 1 | 2010 | 107 | 0.090 |
Why?
| | Hypertension | 5 | 2015 | 1202 | 0.090 |
Why?
| | Airway Remodeling | 2 | 2021 | 63 | 0.090 |
Why?
| | Diet, Ketogenic | 1 | 2009 | 31 | 0.090 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 77 | 0.090 |
Why?
| | Kidney | 1 | 2016 | 1237 | 0.090 |
Why?
| | Anesthesia, Intravenous | 2 | 2021 | 12 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1897 | 0.090 |
Why?
| | Reproducibility of Results | 5 | 2017 | 2948 | 0.090 |
Why?
| | Proteinuria | 1 | 2009 | 103 | 0.090 |
Why?
| | Odds Ratio | 4 | 2014 | 1038 | 0.090 |
Why?
| | Reproductive History | 1 | 2008 | 13 | 0.090 |
Why?
| | Aorta, Thoracic | 1 | 2010 | 243 | 0.090 |
Why?
| | Surveys and Questionnaires | 7 | 2019 | 4842 | 0.090 |
Why?
| | Sex Factors | 4 | 2020 | 1918 | 0.080 |
Why?
| | Asthma | 1 | 2021 | 2016 | 0.080 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 8 | 0.080 |
Why?
| | Cystatins | 1 | 2007 | 6 | 0.080 |
Why?
| | Coronary Angiography | 2 | 2014 | 334 | 0.080 |
Why?
| | Radiography | 3 | 2016 | 860 | 0.080 |
Why?
| | Face | 1 | 2009 | 197 | 0.080 |
Why?
| | Life Style | 1 | 2009 | 408 | 0.080 |
Why?
| | Uric Acid | 1 | 2010 | 360 | 0.080 |
Why?
| | Inflammation | 2 | 2021 | 2538 | 0.080 |
Why?
| | Prognosis | 4 | 2021 | 3549 | 0.080 |
Why?
| | Mortality | 2 | 2019 | 317 | 0.080 |
Why?
| | Apolipoproteins A | 1 | 2006 | 19 | 0.080 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 84 | 0.080 |
Why?
| | Heart Rate | 1 | 2010 | 788 | 0.080 |
Why?
| | Apolipoproteins C | 1 | 2006 | 8 | 0.080 |
Why?
| | Contraception | 1 | 2008 | 129 | 0.080 |
Why?
| | Time Factors | 6 | 2015 | 6906 | 0.070 |
Why?
| | Incidence | 3 | 2019 | 2504 | 0.070 |
Why?
| | Dietary Fats | 1 | 2009 | 353 | 0.070 |
Why?
| | Propensity Score | 2 | 2019 | 251 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2010 | 421 | 0.070 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 69 | 0.070 |
Why?
| | Cluster Analysis | 2 | 2019 | 476 | 0.070 |
Why?
| | Receptors, IgG | 1 | 2005 | 72 | 0.070 |
Why?
| | Internationality | 2 | 2017 | 166 | 0.070 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 397 | 0.070 |
Why?
| | Pregnancy | 3 | 2023 | 5554 | 0.070 |
Why?
| | Chi-Square Distribution | 3 | 2010 | 566 | 0.070 |
Why?
| | Abdominal Wall | 1 | 2004 | 26 | 0.070 |
Why?
| | Antihypertensive Agents | 2 | 2007 | 455 | 0.070 |
Why?
| | Apolipoprotein C-III | 2 | 2019 | 12 | 0.070 |
Why?
| | Haplotypes | 1 | 2006 | 409 | 0.070 |
Why?
| | Hyperlipidemias | 1 | 2005 | 144 | 0.060 |
Why?
| | Glomerular Filtration Rate | 3 | 2016 | 623 | 0.060 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 310 | 0.060 |
Why?
| | Glucose Clamp Technique | 2 | 2017 | 203 | 0.060 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 347 | 0.060 |
Why?
| | Antigens, CD | 1 | 2005 | 470 | 0.060 |
Why?
| | Insulin | 3 | 2022 | 2138 | 0.060 |
Why?
| | Herpesvirus 4, Human | 1 | 2023 | 148 | 0.060 |
Why?
| | Genotype | 3 | 2018 | 1825 | 0.060 |
Why?
| | Blood Platelets | 1 | 2005 | 391 | 0.050 |
Why?
| | Morbidity | 1 | 2022 | 262 | 0.050 |
Why?
| | Muscles | 1 | 2022 | 326 | 0.050 |
Why?
| | Radiography, Thoracic | 2 | 2014 | 179 | 0.050 |
Why?
| | Lung Volume Measurements | 1 | 2021 | 48 | 0.050 |
Why?
| | Biological Variation, Population | 1 | 2021 | 22 | 0.050 |
Why?
| | Artificial Intelligence | 1 | 2022 | 130 | 0.050 |
Why?
| | Protective Factors | 1 | 2021 | 96 | 0.050 |
Why?
| | Hepacivirus | 1 | 2023 | 222 | 0.050 |
Why?
| | Reaction Time | 2 | 2015 | 469 | 0.050 |
Why?
| | Survival Analysis | 2 | 2017 | 1358 | 0.050 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2021 | 46 | 0.050 |
Why?
| | Plethysmography | 1 | 2021 | 139 | 0.050 |
Why?
| | Child, Preschool | 3 | 2023 | 9714 | 0.050 |
Why?
| | Reference Values | 3 | 2010 | 835 | 0.050 |
Why?
| | Anesthesia, General | 1 | 2021 | 46 | 0.050 |
Why?
| | Substance Abuse Detection | 1 | 2021 | 61 | 0.050 |
Why?
| | Hospitals, Urban | 1 | 2021 | 144 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2022 | 305 | 0.050 |
Why?
| | Diabetes Mellitus | 1 | 2009 | 963 | 0.050 |
Why?
| | Cigarette Smoking | 1 | 2021 | 89 | 0.050 |
Why?
| | Hospitals, Pediatric | 2 | 2017 | 488 | 0.050 |
Why?
| | Oligodeoxyribonucleotides, Antisense | 1 | 2019 | 9 | 0.050 |
Why?
| | RNA, Viral | 1 | 2023 | 548 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2021 | 9353 | 0.050 |
Why?
| | Homosexuality, Male | 1 | 2021 | 178 | 0.050 |
Why?
| | rab4 GTP-Binding Proteins | 1 | 2019 | 10 | 0.050 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2019 | 11 | 0.050 |
Why?
| | Cytochrome P450 Family 2 | 1 | 2019 | 13 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2019 | 49 | 0.050 |
Why?
| | Multidetector Computed Tomography | 1 | 2019 | 30 | 0.050 |
Why?
| | Lipids | 2 | 2017 | 638 | 0.050 |
Why?
| | Birth Weight | 1 | 2022 | 451 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2021 | 656 | 0.050 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2019 | 48 | 0.050 |
Why?
| | Bronchodilator Agents | 1 | 2021 | 273 | 0.040 |
Why?
| | Bone Density | 1 | 2022 | 432 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2014 | 1451 | 0.040 |
Why?
| | Europe | 1 | 2019 | 338 | 0.040 |
Why?
| | Electroencephalography | 1 | 2021 | 466 | 0.040 |
Why?
| | Systems Biology | 1 | 2018 | 56 | 0.040 |
Why?
| | Exercise | 1 | 2009 | 1809 | 0.040 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 20 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1012 | 0.040 |
Why?
| | Maternal Health Services | 1 | 2019 | 77 | 0.040 |
Why?
| | Electric Impedance | 1 | 2017 | 106 | 0.040 |
Why?
| | Electrocardiography | 2 | 2010 | 650 | 0.040 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 292 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 517 | 0.040 |
Why?
| | Total Lung Capacity | 1 | 2016 | 45 | 0.040 |
Why?
| | Michigan | 1 | 2017 | 100 | 0.040 |
Why?
| | Glucose | 1 | 2022 | 926 | 0.040 |
Why?
| | Bronchial Arteries | 1 | 2016 | 14 | 0.040 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2017 | 63 | 0.040 |
Why?
| | RNA | 1 | 2023 | 788 | 0.040 |
Why?
| | Causality | 1 | 2017 | 125 | 0.040 |
Why?
| | Urban Population | 1 | 2019 | 421 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 896 | 0.040 |
Why?
| | Area Under Curve | 1 | 2016 | 314 | 0.040 |
Why?
| | Cough | 1 | 2016 | 92 | 0.040 |
Why?
| | Evoked Potentials, Motor | 1 | 2015 | 28 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 507 | 0.040 |
Why?
| | Anesthetics, Intravenous | 1 | 2015 | 34 | 0.040 |
Why?
| | Automation | 1 | 2015 | 79 | 0.040 |
Why?
| | Evoked Potentials, Visual | 1 | 2015 | 41 | 0.040 |
Why?
| | Statistics as Topic | 1 | 2016 | 333 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1019 | 0.030 |
Why?
| | Muscle Strength | 1 | 2018 | 282 | 0.030 |
Why?
| | Physical Endurance | 1 | 2016 | 253 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 499 | 0.030 |
Why?
| | Sex Characteristics | 2 | 2014 | 681 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1155 | 0.030 |
Why?
| | Stroke | 1 | 2003 | 992 | 0.030 |
Why?
| | Plaque, Atherosclerotic | 1 | 2014 | 38 | 0.030 |
Why?
| | Gastroesophageal Reflux | 1 | 2017 | 246 | 0.030 |
Why?
| | Piperidines | 1 | 2015 | 174 | 0.030 |
Why?
| | Mice | 2 | 2021 | 15537 | 0.030 |
Why?
| | Dyslipidemias | 1 | 2015 | 158 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 2014 | 100 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2017 | 528 | 0.030 |
Why?
| | Quality Improvement | 1 | 2021 | 940 | 0.030 |
Why?
| | Angiography | 1 | 2013 | 166 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2019 | 2805 | 0.030 |
Why?
| | Vascular Stiffness | 1 | 2017 | 410 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5136 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 347 | 0.030 |
Why?
| | Exercise Test | 1 | 2014 | 617 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2015 | 1695 | 0.030 |
Why?
| | Gene Frequency | 1 | 2011 | 418 | 0.030 |
Why?
| | Median Nerve | 1 | 2009 | 20 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2016 | 557 | 0.020 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2010 | 119 | 0.020 |
Why?
| | Facial Paralysis | 1 | 2009 | 14 | 0.020 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 89 | 0.020 |
Why?
| | Artifacts | 1 | 2009 | 124 | 0.020 |
Why?
| | Observer Variation | 1 | 2009 | 326 | 0.020 |
Why?
| | Personality Inventory | 1 | 2009 | 154 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 337 | 0.020 |
Why?
| | Animals | 2 | 2021 | 34350 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2009 | 94 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1550 | 0.020 |
Why?
| | Age Factors | 2 | 2007 | 3223 | 0.020 |
Why?
| | Electromyography | 1 | 2009 | 336 | 0.020 |
Why?
| | Diabetic Retinopathy | 1 | 2009 | 135 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 13 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 485 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 24 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 470 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 50 | 0.020 |
Why?
| | Preoperative Care | 1 | 2009 | 323 | 0.020 |
Why?
| | Contraceptive Agents, Female | 1 | 2008 | 76 | 0.020 |
Why?
| | Self Care | 1 | 2009 | 347 | 0.020 |
Why?
| | Patient Selection | 1 | 2010 | 698 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 278 | 0.020 |
Why?
| | Waist-Hip Ratio | 1 | 2004 | 22 | 0.020 |
Why?
| | Hospitalization | 1 | 2014 | 1774 | 0.020 |
Why?
| | Platelet Aggregation | 1 | 2005 | 94 | 0.020 |
Why?
| | Radiography, Abdominal | 1 | 2004 | 35 | 0.020 |
Why?
| | Age Distribution | 1 | 2005 | 382 | 0.020 |
Why?
| | Anthropometry | 1 | 2004 | 211 | 0.020 |
Why?
| | Feeding Behavior | 1 | 2009 | 556 | 0.020 |
Why?
| | Alleles | 1 | 2006 | 775 | 0.020 |
Why?
| | Neoplasms | 1 | 2016 | 2139 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2005 | 1132 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2006 | 1220 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2003 | 330 | 0.010 |
Why?
| | Risk | 1 | 2003 | 926 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2006 | 1253 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1363 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2009 | 2113 | 0.010 |
Why?
| | Child | 1 | 2017 | 18649 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2005 | 1026 | 0.010 |
Why?
| | Infant | 1 | 2009 | 8255 | 0.010 |
Why?
|
|
Kinney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|